싱귤레이트CING 주가

[DEF 14A] 주주총회 위임장 — DEF 14A

[ARS] ARS — ARS

[DEFA14A] DEFA14A — DEFA14A

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.

CING: Building Its Cash Position

By John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported first quarter 2026 results on May 14 th , 2026. For the three-month period, the company generated no revenue and recorded operating expense of $7.9 million. 2025 results were reported only a short time ago; however, over the three months since the end of 2025, the cash balance has

♻️ 재탕[8-K] 중대 사건 — 8-K

[PRE 14A] PRE 14A — PRE 14A

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cash Position Grows to $25.9 MillionKANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead A

Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06) per share from the

[10-Q] 분기 실적 — 10-Q